Chen, W., Wu, Y., Zhu, Q., Jiang, B., Si, L., & Yang, Z. (2026, August). Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China. Expert Review of Pharmacoeconomics & Outcomes Research, 1-12.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Chen, Weiqi, Yongyi Wu, Qiyun Zhu, Bin Jiang, Lei Si, and Zhao Yang. "Cost-effectiveness of Zanubrutinib Versus Ibrutinib as First-line Treatment for Patients with Waldenström Macroglobulinemia in China."
Expert Review of Pharmacoeconomics & Outcomes Research Aug. 2026: 1-12.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Chen, Weiqi, et al. "Cost-effectiveness of Zanubrutinib Versus Ibrutinib as First-line Treatment for Patients with Waldenström Macroglobulinemia in China."
Expert Review of Pharmacoeconomics & Outcomes Research, Aug. 2026, pp. 1-12.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.